Background: Etomidate is the standard induction agent used during rapid sequence intubation (RSI) in the emergency department (ED). Etomidate shortages require providers to utilize alternative agents. The purpose of this study is to compare the safety and procedural outcomes of propofol and etomidate for RSI in the ED. Methods: This was a retrospective chart review of adult patients in the ED who received propofol or etomidate for induction during RSI. The main endpoint was hypotension, defined as a systolic blood pressure < 90 mmHg or diastolic blood pressure < 60 mmHg, within the first hour of intubation. Time to intubation, intensive care unit length of stay, hospital length of stay, and in-hospital mortality were also evaluated. Results: Two hundred and seventy five patient charts were reviewed. Of the 98 patients included, 43 patients received propofol and 55 patients received etomidate. Propofol was associated with an increased incidence of hypotension within the first hour of intubation (65.1% vs. 25.5%, p < 0.001). No difference was found in the time to intubation: ≤5 minutes (51.2% vs. 34.6%, p = 0.83). The mortality rate was 11.6% in the propofol group and 27.3% in the etomidate group (p = 0.004). There was no difference in hospital or intensive care unit length of stay between the propofol and etomidate groups (7.7 vs. 9.2 days, p = 0.23; 4.2 vs. 6.3 days, p = 0.31). Conclusion: Propofol was a safe and procedurally effective induction agent for RSI. Compared to etomidate, it was associated with an increased rate of hypotension within the first hour of intubation, with no difference in the percent of patients that required an intervention.
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Introduction
Rapid sequence intubation (RSI) is the method in which pharmacological agents along with procedural methods are used in quick succession to secure the airway of critically ill patients requiring emergent endotracheal intubation [1] . The purpose of facilitating RSI with pretreatment, sedation, and neuromuscular blocking agents is to effectively secure a patient's airway while minimizing negative outcomes such as aspiration, pain, cervical spine movement, and increased intracranial and intraocular pressure associated with the initiation of intubation [1] [2] . It is important to emphasize that induction with sedation agents must occur before paralyzing patients to avoid consciousness during the procedure.
The choice of an induction agent should be based on the adverse effect profile of the drug and clinical presentation of the patient. Etomidate, a gamma-aminobutyric acid (GABA) agonist is commonly used as an induction agent administered to facilitate a state of unconsciousness [3] [4] . It has an onset of action within 10 -20 seconds and duration of action of 4 to 10 minutes [5] . While etomidate has limited hemodynamic effects making it a desirable choice for quick sedative effects, it does possess unwanted side effects that can be dangerous for certain patient populations [6] . Its inhibition of 11-β-hydroxylase to convert cholesterol to cortisol can lead to adrenal insufficiency and caution should be taken in cases of septic shock with adrenal insufficiency due to controversial data regarding higher mortality rates associated with etomidate administration [7] - [14] .
The onset of action of a bolus dose of propofol is within 10 -50 seconds, with effects lasting between 3 -10 minutes [15] . Although propofol is associated with severe bradycardia and hypotension, it is an optimal choice in hemodynamically stable patients with traumatic brain injuries and reactive airway disease because it does not affect cerebral perfusion and can assist in bronchodilation [15] . Other agents described in the literature, but less commonly seen in clinical practice for this indication include ketamine and midazolam [1] [2] .
In many institutions, etomidate has been the standard induction agent used during RSI procedures in the emergency department (ED). Recent drug shortages have limited etomidate availability and required healthcare professionals to consider alternative agents, such as propofol, for RSI. At our institution, a steady supply of etomidate became unavailable starting in February of 2012 and did not return to adequate levels until June of 2012. Although propofol has been described in the literature for procedural sedation in the ED there are limited data regarding its use for RSI [15] [16] [17] [18] . Despite the common use of these agents during RSI, the safety and efficacy of these two agents has not been compared in randomized controlled trials. This retrospective review evaluates the safety and procedural outcomes of propofol compared to etomidate for induction during RSI in the ED at a large tertiary academic medical center. The main objective of our study was to determine the rate of hypotension within one hour of administration of the induction agent.
Materials and Methods
We performed a single-center, retrospective chart review of adult patients who Vital signs monitored in the ED included blood pressure, heart rate, mean arterial pressure, respiratory rate, temperature, pulse oximetry and oxygenation requirements. Measurements were collected at ED admission and recorded through one hour immediately following the completed intubation. After completion of the procedure, time to extubation was defined as 1) ≤24 hours, 2) >24 hours, and 3) ≥48 hours. Other data collected included hospital length of stay, intensive care unit (ICU) length of stay, and mortality.
The main outcome assessed was hypotension within one hour of induction agent administration. Hypotension was defined as a systolic blood pressure < 90 mmHg or a diastolic blood pressure < 60 mmHg. Minor outcomes assessed included time to intubation, time to extubation, ICU length of stay, hospital length of stay, and in-hospital mortality.
Continuous variables were assessed using Students t-test or Wilcoxon rank sum and non-continuous variables were assessed using Fisher's exact or Chi Squared Test when appropriate. All p values were two tailed and statistically significant at ≤0.05.
Results
Two hundred and seventy five patient charts were reviewed. After exclusion, 98 patients met the inclusion criteria in which 43 patients received propofol and 55 patients received etomidate. A description of the enrollment and exclusions can be found in Figure 1 . Overall, the groups were similar in age, sex, baseline comorbidities, and APACHE II scores. Patient demographics are outlined in Table 1 .
The most common indication for intubation was airway protection. Nineteen patients in the propofol group and 14 patients in the etomidate group needed airway protection, respectively (44.1% vs. 67.3%, p = 0.02). There was no difference between the selection of neuromuscular blocking agents administered between the groups, but succinylcholine was the most popular agent administered in both groups (60.5% vs. 61.8%, p < 0.99) ( Table 2 ).
The main outcome of hypotension within one hour of administration of the induction agent occurred in 28 patients in the propofol group and 14 patients in the etomidate group (65.1% vs. 25.5%, p < 0.0001). Of the 42 patients that had recorded hypotension, only 27 patients needed an intervention to reverse the episode (67.8% in the propofol group vs. 57.1% in the etomidate group, p = 0.51).
Interventions to reverse the hypotensive episode included additional intravenous fluid boluses, initiation of vasopressor agents, or a combination of the two. Median (Interquartile Range); SCr = serum creatinine; BUN = blood urea nitrogen; WBC = white blood count; SBP = systolic blood pressure; DBP = diastolic blood pressure; MAP = Mean Arterial Pressure. There was no difference in the rate of fluid or vasopressor administration between the groups (Table 3 ).
The rate of failed intubations (4.6% vs. 5.5%) and oral trauma (2.3% vs. 3.6%)
was not found to be statistically significant between the propofol and etomidate groups respectively. The mean hospital length of stay was 7.7 and 9.2 days and ICU length of stay was 4.7 and 6.3 days in the propofol compared to etomidate group. The recorded rate of mortality was 11.6% in the propofol group compared to 27.3% in the etomidate group (p = 0.004) ( Table 4 ).
Discussion
In this retrospective chart review analysis comparing propofol and etomidate for induction during RSI, we found that both agents have similar safety and procedural outcomes profiles. When reviewing the charts for RSI procedural records, all medications, such as fentanyl, lidocaine and/or midazolam for pretreatment were appropriately dosed and administered before the RSI procedure. Both agents had similar rates of oral trauma, failed intubations, time to intubation, and time to extubation. The mean dose of propofol was 1.1 mg/kg and etomidate was 0.26 mg/kg, which are slightly lower than the recommended doses for induction during RSI [5] [15] . There were no records of additional adverse events recorded in the chart review related to the administration of either induction agent.
As expected, propofol had a higher rate of hypotension within the first hour after the induction agent was administered. Although propofol had a significantly higher rate of hypotension compared to etomidate (65.1% vs. 25.5%, p < 0.0001), there was no difference in the number of patients who required an intervention to address these events and all episodes were recorded without longterm adverse events. Of those patients in each group that did require an intervention, they received fluid boluses with sodium chloride 0.9%, vasopressor agents (norepinephrine, phenylephrine, vasopressin), or both. For patients that were already receiving fluids or vasopressor agents before initiation of RSI and had a recorded hypotensive event within one hour after administration of the induction agents, increases in the rate of the vasopressor agents or additional fluid boluses were considered an intervention. Some hypotensive events might have been associated with fluctuations in ventilator settings, the use of continuous sedative infusions for sedation (i.e. propofol, midazolam) or other undocumented physiological changes unrelated to the induction agent administered. This could explain the resolution of hypotension in the 15 (35.6%) patients with a documented hypotensive event that did not require additional intravenous fluids or initiation of a vasopressor. Unfortunately, this hypothesis cannot be confirmed due to the fact that not all charts had recorded ventilator settings or documented titration of continuous sedation agents. The majority of the charts only confirmed the initial ventilator settings and rate of continuous sedation immediately after the placement of the endotracheal tube.
The overall mortality rate was 25.5% in both the propofol and etomidate groups combined. The mortality rate recorded in the etomidate group was higher compared to the propofol group (27.3% vs. 11.6%, p < 0.004). We found that a large majority of patients in both groups needed to be intubated for airway protection (44.1% vs. 67.3%, p < 0.025). After looking at the population demographics in more detail of each patient intubated for airway protection, more patients in the etomidate group were admitted to the ED for a traumatic brain injury and intracerebral hemorrhages. Although the severity of illness is comparable in the two groups, it can be presumed that the patient population in the etomidate group had a higher baseline mortality risk based on the requirement for hospital admission and clinical presentation. It has been reported in previous literature that etomidate can be associated with increased risk of death after a single dose, but this cannot be correlated to our investigation.
Limitations
There are several limitations in this study. This was a single-center, retrospective, Regarding our statistical analysis, the secondary outcome of in-hospital mortality did not include a multivariate test for associated risk factors for increased mortality risks. Since this was not analyzed, higher rates of mortality in the etomidate group compared to propofol cannot be directly correlated to its administration.
Conclusion
Propofol was associated with an increased rate of hypotension within the first hour of intubation; however, there was no difference in the percent of patients that required an intervention to treat the hypotensive event. Other endpoints suggest there were no further clinically significant differences between the two groups in adverse events or failed intubations. It appears that both of these pharmacological agents are similar in safety and procedural outcomes for use in RSI in the ED. The increased mortality rate found with etomidate warrants fur-ther analysis comparing these two agents during RSI.
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